# Allergy Therapeutics positive primary results from peanut allergy vaccine candidate

- Link: https://www.directorstalkinterviews.com/allergy-therapeutics-positive-primary-results-from-peanut-allergy-vaccine-candidate/4121014118
- Published: 2021-08-03T07:21:35+01:00
- Author: Giles

**Allergy Therapeutics plc** ([LON:AGY](https://www.directorstalkinterviews.com/company/allergy-therapeutics/agy.l)),
the fully integrated commercial biotechnology pharmaceutical company specialising
in allergy vaccines, has announced positive primary results from an _ex-vivo_ biomarker
study evaluating the Group’s novel virus-like particle (VLP) based peanut allergy
vaccine candidate.

–     _Study results confirm peanut vaccine candidate’s hypoallergic potential_

–     _Findings support VLP Peanut first in-human Phase I study design, on track
to start Q1 2022_

–     _Short-course peanut allergy vaccine candidate represents a significant opportunity
in $8 billion worldwide food allergy market_

–     _Results strengthen Phase I study IND application being submitted to US FDA
in late 2021_

The study, which took place at Imperial College London, evaluated the Group’s short-
course VLP Peanut and aimed to demonstrate the vaccine candidate’s hypoallergic 
potential. If a vaccine is hypoallergenic, it means it does not illicit an allergic
reaction in patients upon dosing. The study used blood samples from peanut allergy
patients to evaluate an extensive set of functional and molecular biomarkers. This
resulted in a successful primary outcome, with the trial demonstrating a significant
24-fold reduction in basophil activation and histamine release after blood samples
were challenged with VLP Peanut compared to a recombinant peanut extract, signifying
the hypoallergenic potential of the vaccine candidate. These positive clinical data
add to the Group’s strong pre-clinical research package, which has demonstrated 
sustained immunologic protection following peanut exposure after just one single
vaccination.

The biomarker study results are encouraging and provide strong support for the human
translation of the pre-clinical results and strong confidence in the data to be 
generated in the planned Phase I study (the PROTECT study). The data also provide
important information to establish the starting dose for PROTECT, which is expected
to commence in Q1 2022.  

Moreover, the results from this study further strengthen the Group’s Investigational
New Drug (IND) application with the United States Food and Drug Administration (
FDA), which is expected to be submitted in late 2021. Further data will be released
in due course once secondary endpoints of the study have been analysed.

In addition, the Group has also recently completed an extensive multiple dose toxicology
study with VLP Peanut, applying the maximum subcutaneous doses expected to be administered
in clinical trials, which further supports the dose escalations planned in the first
in-human Phase I study. More information on VLP Peanut will be provided by the Group
at a Key Opinion Leader investor event, currently planned for September 2021.

VLP Peanut is being developed as a novel VLP-based therapy for the treatment of 
peanut allergy. This novel immunogenic, protective, and non-reactogenic vaccine 
candidate is based on immunologically optimised Cucumber Mosaic Virus-derived VLPs(
CuMVTT) with the major peanut allergen (_Arachis hypogaea_) (Ara h 2) displayed 
on its surface. Patents behind the technology to treat peanut allergy with VLP Peanut
have now been granted in the US and are at the national phase in other territories.

The potential of an effective short-course peanut allergy vaccine represents a significant
opportunity in the $8 billion worldwide food allergy market^(1). Peanut allergy 
is one of the most common types of food allergy and its symptoms can range from 
mild to severe and life-threatening. In the western world, the prevalence of peanut
allergy doubled between 2005 and 2015 and it is becoming apparent in Africa and 
Asia^(2). Only about 20% of children diagnosed with peanut allergy outgrow it by
the time they reach school age. In the US (as of 2014), peanut allergy was the most
common cause of severe and fatal food-induced anaphylactic reactions^(3).

> **Manuel Llobet, CEO of Allergy Therapeutics, stated:** “We are pleased to have
> reached this important milestone in the development of our ground-breaking and
> disruptive vaccine candidate, VLP Peanut. Through our collaboration with Imperial
> College London and the dedication of our clinical and R&D teams at Allergy Therapeutics,
> we are another step closer to offering a potentially transformative treatment 
> option for one of the most dangerous allergies. I am proud of the work we do in
> helping to transform patients’ lives and look forward to our upcoming IND submission
> at the end of this year and expected initiation of our Phase I PROTECT trial in
> 2022.”

Share on:
